Key facts
- AGED Diagnostics’s last known valuation is $11.0M (Feb 2025).
- It has raised $3.5M; the latest was Accelerator/Incubator in Oct 2025.
- Notable investors include Plug and Play Tech Center, TEDCO, Bioincubator, Mimosa Ventures, 757 Collab — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for AGED Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for AGED Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AGED Diagnostics
Operator of a biotechnology company intended to create a non-invasive test for liver disease. The company focuses on using transcriptional genetic analysis to identify the patterns of early tumorigenesis, enabling medical researchers to obtain an accurate depiction of their patients' health.
- Sector
- Healthcare
- HQ
- Bethesda, MD, United States
- Founded
- 2018
- Employees
- 5
- Website
- ageddiagnostics.com/
- Ownership
- Privately Held (backing)
AGED Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AGED Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AGED Diagnostics in its N-PORT filings yet. We sweep new filings monthly.